% | $
Quotes you view appear here for quick access.

Elan Corporation, plc Message Board

bocamp1 207 posts  |  Last Activity: 10 hours ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What profit number for 2014

    by jernst1959 17 hours ago

    Why is that resell?. I am a much larger investor here for a much longer period of time than you or most everyone else here except maybe smalls. I know that cause I organized many shareholders a while back. So believe me, all that i want is for this stock to go up. My main problem with management is that they dont seem to care about share price. When that changes and management walks that walk, instead of their worthless talk, i will be very happy.
    Management has criticized me because i have said to them that share price is the only metric that counts for a public company. So, again reseller, you are very wrong, but consistent.

  • Reply to

    What profit number for 2014

    by jernst1959 17 hours ago

    A breakeven would be really nice along with some realistic forward guidance about non eecp medical device sales.

  • Reply to

    Somebody just bought 83,300

    by jernst1959 Mar 27, 2015 1:40 PM

    Management must be careful(non transparent) because they do not want to call attention to thier lies, overcompensation, and incompetence.
    Ma's old lies extend to hype about India's to saying in an SEC doc they will be profitable in 2014. Their incompetence is very obvious; failing on eecp, paying a flunky to get better insurance coverage, the Dempsy fiasco, the lawsuits, the non accretive acquisitions(could also be put in the lie area), and incestous nature for employees in acquisitions.................could go on.........stock price.
    Overcompensation; who thinks Ma should have a package valued at 600,000?

  • Reply to

    Jump the ship

    by gkas711 Mar 27, 2015 2:37 PM
    bocamp1 bocamp1 Mar 27, 2015 6:31 PM Flag

    No shorts today at all. This follows my assumption that the runnup on little news inspired some not so deep pocket day traders(tweeter) to get involved in a stock they know or care nothing about. They are just trying to cash out and move on. They sell stupidly. Supply should be done soon but does provide any investors who know the real story here to take advantage of this weakness. Of course, you need a pair which is something most here dont seem to have(SNO). Or you could be just like dimwitted hollis and wait for 10 cents.
    Fink should try to get this stock on an elevated OTC exchange. The trading here on little volume is criminal.

  • Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares down 21 percent in premarket trading on Friday.

    The study tested the drug, OHR-102, in combination with Roche Holding AG's Lucentis, in patients with the wet form of age-related macular degeneration, the leading cause of blindness in the elderly

  • Short, message board legal "experts" working overtime today. At a buck a post, they are soon to be part of the 1% er's. Who needs a real patent attorney when we have these Rhodes Scholars.
    Shorts are really desperate if they have to employ these More Ons...................................

  • bocamp1 by bocamp1 Mar 26, 2015 10:42 AM Flag

    Wonder why? What a nutjob

  • Reply to

    Bio Tech Reversal..?

    by hanskrumbholz Mar 26, 2015 9:45 AM
    bocamp1 bocamp1 Mar 26, 2015 10:14 AM Flag

    This action has nothing to do with a reversal in the general bio market. Look at the april calls. They are now paying 25 cents for the april 5's. Action in sgyp specific and suggest early buyout here. Follow the money

  • bocamp1 by bocamp1 Mar 26, 2015 9:47 AM Flag

    Very aggressive buying in the april calls this morning. News very soon.

  • bocamp1 by bocamp1 Mar 25, 2015 9:42 PM Flag

    These comments are from an older report which is being updated. Zacks, at no point, questions rgrx's IP protection despite what our knucklehead, message board, crack legal team of Donk and Hollis whine about endlessly. Buy the dips

    RegeneRx holds approximately 150 issued patents and filed patent applications worldwide within 14 patent families.
    These patients cover peptide compositions, uses and formulations related to dermal and ophthalmic indications and
    other organ and tissue repair and regenerative medicine activities, as well as for cosmetic and consumer
    applications with Thymosin beta-4 and its related fragments. These include T 4 patents licensed from the NIH
    issued in the U.S., Europe, and Asia. These patents begin to expire in July 2019. The company has also licensed all
    rights to T 4 applications in respiratory distress syndrome and septic shock from The George Washington
    University (GWU), for which, if commercialized, RegeneRx will pay GWU a 4% royalty on sales in these areas.
    RegeneRx has filed numerous additional U.S. and international patent applications covering various compositions,
    uses, formulations and other components of T 4.

  • Restasis is a used to increase the eyes ability to produce tears, which may be deficient in patients with ocular
    inflammation. It effectively masks the symptoms of dry eyes, but does not go after the underlying cause of the
    disease. It s a step-up from OTC dry eye products like Refresh, but does not heal corneal surface defects such as
    ulcerations or neurotrophic keratitis (NK). Despite its limitations, for 2011, Allergan sees Restasis sales between
    $680 and $710 million. We think there is a significant unmet medical need for a product like RGN-259, a potential
    disease modifier, to treat dry eye patients where Restasis fails. At the very least, the RGN-259 my find use in
    combination with Restasis to improve tear production and corneal healing

  • Reply to

    Major Volume today

    by fl_geezer Mar 25, 2015 4:59 PM
    bocamp1 bocamp1 Mar 25, 2015 6:15 PM Flag

    Only 2200 shorted. Stock is getting into stronger hands as trader took profits today. Meaningless to the real story here

  • Reply to

    Major Volume today

    by fl_geezer Mar 25, 2015 4:59 PM
    bocamp1 bocamp1 Mar 25, 2015 5:06 PM Flag

    I dont think you will see much short. I think one of the tweeterhead traders who bought the runnup was getting out. Overall, a good day as stock came back nicely and bidders edge higher towards the close.
    Might see a Zacks update very soon.

  • Reply to

    Huge Call Volume

    by bocamp1 Mar 25, 2015 12:24 PM
    bocamp1 bocamp1 Mar 25, 2015 4:50 PM Flag

    Crazy option trading here on a crushing day in the market. Near the close, a buyer of 2500 of the may double nickel calls at 25 cents, when the bid was 5 cents. That option went to 40 cents as stock headed lower. Many April and Julys also bought. Big premuim expansion......................why?
    Maybe big player taking a postion in equity and front running in the option market.

  • bocamp1 by bocamp1 Mar 25, 2015 12:24 PM Flag

    Big buyers in the april 48 calls. Follow the money.

  • Our 2 message board lawyers are hard at work. Good for them. Where else can one get such astute, free legal advice. ?

  • Reply to

    Donk Gets More Manic as Stock Goes Higher

    by bocamp1 Mar 24, 2015 12:14 PM
    bocamp1 bocamp1 Mar 24, 2015 6:20 PM Flag

    This will be an interesting season for RGRX.....

    That's for sure...

  • Reply to

    Call Buyers Today paying Big Premium

    by bocamp1 Mar 24, 2015 4:43 PM
    bocamp1 bocamp1 Mar 24, 2015 4:48 PM Flag

    Shorts has tried to say trial wont work or will be delayed. But todays Agreement anouncement confirms results in late April. Call volume supports trial success. May is the place to be

  • About 900 of the may 40 calls done today. One large buyer on the offer of 376 contracts at 8.6. Some puts sold to pay for them, but stock has to run quite a bit to get those ITM.

  • bocamp1 by bocamp1 Mar 24, 2015 4:31 PM Flag

    Late buyer of 1000 july 5 calls; all on offer. 200 at .5 and then 800 at .55. Plenty of money to be made here at the shorts expense.